Loading…
Atea Pharmaceuticals, Inc. is projected to rise to $6.03 by 2027, a +21% move from its current price of $4.99. AVIR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $4.89 | $4.99 | $5.09 | +0.02% |
| Jul 14 | $4.85 | $4.99 | $5.14 | +0.05% |
| Jul 15 | $4.82 | $4.99 | $5.17 | +0.07% |
| Jul 16 | $4.79 | $4.99 | $5.20 | +0.09% |
| Jul 17 | $4.77 | $5.00 | $5.23 | +0.11% |
| Jul 18 | $4.75 | $5.00 | $5.25 | +0.14% |
| Jul 19 | $4.73 | $5.00 | $5.28 | +0.16% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.73 | $5.00 | $5.28 | +0.16% |
| Week 2 | $4.64 | $5.01 | $5.41 | +0.32% |
| Week 3 | $4.56 | $5.01 | $5.51 | +0.48% |
| Week 4 | $4.50 | $5.02 | $5.60 | +0.64% |
| Week 5 | $4.45 | $5.03 | $5.68 | +0.80% |
| Week 6 | $4.41 | $5.04 | $5.76 | +0.96% |
| Week 7 | $4.37 | $5.05 | $5.83 | +1.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.
Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company is also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection, and offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. Atea Pharmaceuticals, Inc.
was incorporated in 2012 and is headquartered in Boston, Massachusetts.
The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir.
Atea Pharmaceuticals, Inc. (AVIR) is publicly traded with a current price of $4.98 and a market capitalization of $398.53M. It ranks 3152 by market cap among listed assets.
The price outlook reflects a multi-year forecast with the average price expected to rise over time, beginning at $4.98 in 2026 and moving higher in later years. The forecast shows a sequence of higher averages—from $4.98 in 2026 to $8.84 by 2030, then extending to $55.32 by 2050—accompanied by substantial increases in return on investment across the horizon.
A major floor 20.8% below — a decisive break under it would weaken the trend.
The nearest floor, 15.6% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 23.2% above — clearing it would confirm fresh momentum.
Key AVIR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AVIR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.89 | Buy | $4.89 | Buy |
| MA 10 | $4.80 | Buy | $4.80 | Buy |
| MA 20 | $4.59 | Buy | $4.69 | Buy |
| MA 50 | $4.69 | Buy | $4.72 | Buy |
| MA 100 | $5.08 | Sell | $4.70 | Buy |
| MA 200 | $4.22 | Buy | $4.40 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 62.74 | Neutral |
| Stoch RSI (14) | 89.91 | Sell |
| CCI (20) | 123.09 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.07 | Buy |
| ROC (12) | 11.38 | Buy |
| Bollinger %B (20,2) | 0.92 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.09 | Buy |
| Awesome (5,34) | 0.38 | Buy |
| Ultimate (7,14,28) | 71.92 | Sell |
| Momentum (10) | 0.64 | Buy |
| Aroon Osc (25) | 100.00 | Buy |
| Hull MA (9) | 4.93 | Buy |
| ADX (14) | 17.43 | Neutral |
| ATR (14) | 0.10 | Info |
The near-term technical stance is BULLISH. The RSI14 is 60, indicating modest upward momentum. The 50-day simple moving average is $4.75 and the 200-day simple moving average is $4.17, suggesting the price is trading above longer-term averages.
Support is identified at $4.19 and resistance at $4.98, with a 30-day price range from $4.29 to $5.78. These levels provide a framework for potential moves in the coming weeks as the price tests the upper bound near the resistance and the lower bound near the support.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.40 | $4.99 | $6.43 | 0% | Neutral | |
| $4.91 | $6.03 | $7.77 | +21% | Bullish | |
| $5.39 | $6.76 | $8.95 | +35% | Bullish | |
| $5.96 | $7.60 | $10.30 | +52% | Bullish | |
| $6.49 | $8.40 | $11.60 | +68% | Bullish | |
| $8.11 | $10.63 | $14.94 | +113% | Bullish | |
| $9.77 | $12.96 | $18.49 | +160% | Bullish | |
| $10.02 | $13.46 | $19.46 | +170% | Bullish | |
| $11.01 | $14.95 | $21.90 | +200% | Bullish | |
| $11.85 | $16.25 | $24.09 | +226% | Bullish | |
| $19.71 | $28.34 | $44.16 | +468% | Bullish | |
| $32.41 | $50.38 | $84.54 | +910% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.40 | $4.99 | $6.05 | +0.00% |
| August 2026 | $4.42 | $5.18 | $6.21 | +3.83% |
| September 2026 | $4.32 | $5.09 | $6.16 | -1.67% |
| October 2026 | $4.32 | $5.12 | $6.23 | +0.43% |
| November 2026 | $4.41 | $5.24 | $6.41 | +2.33% |
| December 2026 | $4.38 | $5.22 | $6.43 | -0.27% |
Click any year to see its month-by-month AVIR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect AVIR to range from $3.40 to $6.43 through 2026. The $4.99 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The AVIR price prediction for 2027 points to an average of $6.03 (low $4.91, high $7.77) — a potential gain of +21% on today's $4.99. Momentum favours further upside here.
In 2028, AVIR is projected to trade between $5.39 and $8.95, averaging $6.76 — a potential gain of +35% from today's $4.99. That is up +12% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Atea Pharmaceuticals, Inc.'s 2029 outlook centres on $7.60, within a $5.96 to $10.30 range. That is up +12% on the projected 2028 average. That marks a +52% change versus current levels. Momentum favours further upside here.
By 2030, AVIR could reach as high as $11.60, with a base case around $8.40 and support toward $6.49 — roughly +68% from $4.99. Buyers look set to stay in control over this stretch.
Expect AVIR to range from $8.11 to $14.94 through 2031. The $10.63 average target implies a +113% move from current prices. That is up +27% on the projected 2030 average. Momentum favours further upside here.
The AVIR price prediction for 2032 points to an average of $12.96 (low $9.77, high $18.49) — a potential gain of +160% on today's $4.99. Buyers look set to stay in control over this stretch.
In 2033, AVIR is projected to trade between $10.02 and $19.46, averaging $13.46 — a potential gain of +170% from today's $4.99. That is up +4% on the projected 2032 average. Momentum favours further upside here.
Atea Pharmaceuticals, Inc.'s 2034 outlook centres on $14.95, within a $11.01 to $21.90 range. That is up +11% on the projected 2033 average. That marks a +200% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, AVIR could reach as high as $24.09, with a base case around $16.25 and support toward $11.85 — roughly +226% from $4.99. Momentum favours further upside here.
Expect AVIR to range from $19.71 to $44.16 through 2040. The $28.34 average target implies a +468% move from current prices. That is up +74% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The AVIR price prediction for 2050 points to an average of $50.38 (low $32.41, high $84.54) — a potential gain of +910% on today's $4.99. Momentum favours further upside here.
Investing $1,000 in AVIR today (≈ 200.400802 AVIR) could be worth
$10,096.64
+$9,096.64 (+910%) by 2050 · US Dollar
Based on the average projected AVIR price of $50.38 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AVIRwould be worth at today's price.
$1,000 invested in AVIR on Jul 10, 2025 (≈ 264.550267 AVIR) would be worth
$1,320.11
+$320.11 (+32.0%) today · 1.32× · US Dollar
Based on a AVIR entry price of $3.78 vs. today's $4.99.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.98 | $1,002.01 | +0.2% |
| 1 month ago | $4.39 | $1,136.67 | +13.7% |
| 3 months ago | $5.67 | $880.07 | -12.0% |
| 6 months ago | $3.61 | $1,382.27 | +38.2% |
| 1 year ago | $3.78 | $1,320.11 | +32.0% |
| All time (5.0y) ago | $22.25 | $224.27 | -77.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AVIR forecast.
Our base-case forecast reaches $10.00 around 2031.
Implied market cap at $10.00: $800.27M
The multi-year forecast shows a bullish trajectory from 2027 onward, with increasing average prices and rising ROI. The path begins with an average of $6.17 in 2027 (ROI 23.9) and ascends to $8.84 in 2030 (ROI 77.5), continuing to higher levels in subsequent years.
Key long-term milestones include a 2040 average of $30.91 (ROI 520.6) and a 2050 average of $55.32 (ROI 1010.8). The sentiment is BULLISH across the later years, reflecting an expectation of continued price growth relative to the current level. These figures are estimates and not guarantees, and actual results may differ due to market dynamics and other factors.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $8.84, with a min of $6.75 and a max of $12.40, and a ROI of 77.5%; sentiment is BULLISH.
The forecast portrays a bullish path from 2027 onward with rising averages and a high ROI by 2050 (average $55.32, ROI 1010.8%), but these are estimates and not guarantees.
Yes. The 2033 max is $21.12 and the 2034 max is $23.85, with subsequent years also showing higher max values, indicating possible attainment of $20 in later years.
Current price is $4.98 and market cap is $398.53M.
The 30-day range is $4.29 to $5.78. Support is at $4.19 and resistance is at $4.98. RSI14 is 60, SMA50 is $4.75, and SMA200 is $4.17.
Atea Pharmaceuticals, Inc. Community Discussion
0Share your Atea Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.